Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4).

Fiche publication

Date publication

octobre 2017

Journal

Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier , Pr CONROY Thierry

Tous les auteurs :
Robert M, Jarlier M, Gourgou S, Desseigne F, Ychou M, Bouché O, Juzyna B, Conroy T, Bennouna J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28982109

Résumé

Carbohydrate antigen 19-9 (CA19-9) is a sensitive and specific serum marker in pancreatic cancer. Our retrospective analysis aims to evaluate CA19-9 decrease in patients with metastatic pancreatic cancer treated in ACCORD11/PRODIGE4 (FOLFIRINOX vs. gemcitabine).